- Home
- CCK vs PODD Comparison
CCK vs PODD Comparison
Compare CCK & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCK | PODD |
|---|---|---|
| Founded | 1906 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 10.2B |
| IPO Year | 2003 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CCK | PODD |
|---|---|---|
| Price | $116.61 | $149.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 26 |
| Target Price | $136.15 | ★ $167.17 |
| AVG Volume (30 Days) | 781.4K | ★ 1.3M |
| Earning Date | 10-19-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 79.72 | N/A |
| EPS | ★ 3.78 | 2.67 |
| Revenue | ★ $11,665,000,000.00 | $2,708,100,000.00 |
| Revenue This Year | $13.34 | $21.37 |
| Revenue Next Year | $2.39 | $13.57 |
| P/E Ratio | ★ $30.83 | $56.18 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $91.31 | $126.40 |
| 52 Week High | $122.91 | $354.88 |
Technical Indicators
Market Signals| Indicator | CCK | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 61.12 | 66.88 |
| Support Level | $113.11 | $139.67 |
| Resistance Level | $122.11 | $153.33 |
| Average True Range (ATR) | 2.64 | 4.19 |
| MACD | 0.91 | 1.75 |
| Stochastic Oscillator | 74.01 | 97.40 |
Price Performance
Historical ComparisonAbout CCK Crown Holdings Inc.
Crown Holdings Inc is a producer of metal packaging. The company manufactures beverage cans, metal food cans, and closures, as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.